VERVE-102 is an investigational gene-editing treatment designed to permanently disable the PCSK9 gene in the liver, thereby ...

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk ...

Multisystemic smooth muscle dysfunction syndrome (MSMDS) is a rare condition associated with stroke, aortic dissection (tearing) and death in childhood. Currently ...

A groundbreaking gene-editing therapy developed by Eli Lilly and Verve Therapeutics reduced "bad" LDL cholesterol by up to 62 ...

Urnov is a professor of molecular therapeutics at the University of California, Berkeley, and a director at its Innovative Genomics Institute. In May, news broke of a biomedical first: the on-demand ...

Rothamsted Research launches inaugural field trial under the Precision Breeding Act as investment in crop biotechnology signals growing momentum for next-generation agricultural innovation The United ...

Early CRISPR-based cholesterol therapy shows striking LDL reduction, but experts warn that safety, durability and off-target ...

It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...

A new gene-editing technique enables the correction of multiple genetic mutations simultaneously, transforming the prospects for millions living with complex inherited diseases, such as cystic ...

Researchers from the Department of Biomedical Engineering at UNIST and the Center for Genomic Integrity at the Institute for Basic Science (IBS) have announced an advance in cancer gene therapy. Their ...

Learn how CRISPR ETFs provide access to the gene-editing revolution, offering investors a diversified approach without picking individual biotech stocks.